Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 6, 2015, Pages

  Mammen, Andrew L ^a,b   Casciola Rosen, Livia ^b   Christopher Stine, Lisa ^b   Lloyd, Thomas E ^b   Wagner, Kathryn R ^b,c  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HMGCR ANTIBODY; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; MDA5 ANTIBODY; MI2 ANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; NXP2 ANTIBODY; SRP ANTIBODY; TIF1G ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; GENETIC DISORDER; GENETIC MUSCLE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIMB GIRDLE MUSCULAR DYSTROPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MUSCLE DISEASE; MUSCLE WEAKNESS; MYOSITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RASH; SENSITIVITY AND SPECIFICITY;

EID: 84952905211     PISSN: 23327812     EISSN: None     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000172     Document Type: Article

References (15)

1. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci 2010;1184:134-153.
2. Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011;305:183-190.
3. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands. Neuromuscul Disord 2004;14: 337-345.
4. Hengstman GJ, van Brenk L, Vree Egberts WT, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol 2005;252:534-537.
5. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012;24:602-608.
6. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-721.
7. Pinal-Fernandez I, Casciola-Rosen L, Christopher-Stine L, Corse A, Mammen A. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from dermatomyositis patients. J Rheumatol 2015;42:1448-1454.
8. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65:2954-2962.
9. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757-2766.
10. Amato AA, Griggs RC. Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003;61: 288-289.
11. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316-321.
12. Claeys KG, Gorodinskaya O, Handt S, et al. Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology 2013;81:932-935.
13. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201: 591-601.
14. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen mi-2 in regenerating muscle. Arthritis Rheum 2009;60:3784-3793.
15. Mohassel P, Rosen P, Casciola-Rosen L, Pak K, Mammen AL. Expression of the dermatomyositis autoantigen transcription intermediary factor 1 gamma in regenerating muscle. Arthritis Rheumatol 2015;67:266-272.